Corrected PDMP Survey
Corrected Survey on the SUPPORT Act's Prescription Drug Monitoring Program Mandate
We want to inform you that we encountered technical issues with the survey regarding the SUPPORT Act's PDMP mandate. We apologize for any inconvenience this may have caused. If you attempted to take the survey previously, please try again. If you have not participated yet, we encourage you to take the survey now. Your feedback is essential in helping us assess the implementation of this mandate. The survey will take approximately 5 minutes, and your responses will remain confidential.
Updates to Coverage of Continuous Glucose Monitors (CGMs)
Updates to Coverage of Continuous Glucose Monitors (CGMs):
Effective August 29, 2024, MO HealthNet will expand coverage of Continuous Glucose Monitors (CGMs) to participants currently diagnosed with Gestational Diabetes allowing this vulnerable population to obtain a CGM without a prior authorization. Claims for a CGM will auto-approve if the participant has had a gestational diabetes diagnosis billed to MO HealthNet recently OR if the pharmacy submits the appropriate gestational diabetes diagnosis code with the claim.
Opioid Use ECHOs
Opioid Use Disorders ECHO
New Provider Obstetric Resource Workbooks from the MO PQC
New Provider Obstetric Resource Workbooks from the MO Perinatal Quality Collaborative
Improving the health outcomes of maternal and infant populations is a critical priority in Missouri. The Missouri Perinatal Quality Collaborative (PQC) is working to close gaps to achieve equitable and improved health outcomes.
Opioid Reversal Agents
Opioid Reversal Agents
In 2021, nearly 1 out of 47 deaths in Missouri were attributed to an opioid-involved overdose. Naloxone is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.